Synthes/Mathys merger
Synthes is "prepared to appeal" an anti-trust ruling prohibiting the German portion of its $1.1 bil. purchase of Mathys' osteosynthesis business, pending a "careful" analysis of the regulatory body's (Bundeskartellamt) decision, Synthes says March 29 (1"The Gray Sheet" Feb. 16, 2004, In Brief). The bulk of the Aug. 13 Mathys divestiture closed Feb. 6, excluding the German operations...
More from Archive
More from Medtech Insight
Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.
The US FDA has published its final document to guide sponsors on using sex-specific data in designing clinical trials of medical devices. However, the guidance removes all references to gender that appeared in January’s draft guidance, released before the Trump administration took office.